Why is a gonadotropin‑releasing hormone (GnRH) agonist administered when fertility preservation is desired in patients undergoing gonadotoxic chemotherapy or radiation?

GnRH Agonists for Fertility Preservation During Chemotherapy

Direct Answer

GnRH agonists should be offered to all premenopausal patients undergoing gonadotoxic chemotherapy to reduce the risk of premature ovarian insufficiency and preserve ovarian function, but they do NOT replace established fertility preservation methods like embryo or oocyte cryopreservation. 1

Primary Indication: Ovarian Function Preservation, Not Fertility Preservation

The most recent high-quality guideline (ESO-ESMO 2022) confirms that GnRH agonists concomitant with chemotherapy should be offered to reduce premature ovarian insufficiency risk and possibly preserve ovarian function. 1 However, this is fundamentally different from fertility preservation:

• GnRH agonists preserve ovarian function (maintaining menstrual cycles and hormone production), which improves quality of life by preventing early menopause 1
• They do NOT reliably preserve fertility (ability to conceive), as fertility outcome data after temporary ovarian suppression remains insufficient 1
• Established fertility preservation methods (embryo/oocyte cryopreservation) remain the gold standard and must still be offered to all patients interested in future pregnancy 1

Mechanism of Action (Theoretical)

GnRH agonists may protect ovaries through several proposed mechanisms, though the exact pathway remains debated:

• Simulating prepubertal state: Decreasing gonadotropins reduces the number of primordial follicles entering the differentiation stage, which is more vulnerable to chemotherapy 2, 3
• Reduced ovarian perfusion: The hypoestrogenic state decreases blood flow and chemotherapy delivery to ovaries 2, 3
• Direct ovarian effects: GnRH receptors on ovaries may be directly affected, independent of gonadotropin suppression 2, 3
• Anti-apoptotic upregulation: May increase protective molecules like sphingosine-1-phosphate 2, 3

Evidence Quality and Guideline Evolution

The evidence has evolved significantly, with the most recent guidelines being more supportive:

Most Recent (2022): The ESO-ESMO BCY5 guidelines state GnRH agonists should be offered to all patients, representing the strongest current recommendation. 1

Intermediate (2018): ASCO guidelines show mixed recommendations across societies, with Italian (AIOM 2016) and Spanish (SEOM 2016) guidelines supporting use, while NCCN AYA Oncology (2017) and ESMO (2013) remained skeptical. 1

Historical (2006): ASCO initially stated insufficient evidence and recommended use only in clinical trials. 1

Clinical Application Algorithm

Step 1: Discuss ALL fertility preservation options early 1

• Refer to reproductive specialist immediately for embryo/oocyte cryopreservation 1
• These remain the only proven fertility preservation methods 1

Step 2: Offer GnRH agonist for ovarian function preservation 1

• Indicated for all premenopausal patients undergoing chemotherapy who want to reduce premature ovarian insufficiency risk 1
• Works in both hormone receptor-positive and receptor-negative breast cancer with no signal for harm regarding recurrence 1

Step 3: Coordinate timing 1

• GnRH agonist efficacy appears unrelated to timing before chemotherapy 1
• Schedule after oocyte cryopreservation to avoid ovarian hyperstimulation syndrome 1
• Coordinate between fertility and oncology teams 1

Step 4: Set realistic expectations 1

• Patients will experience short-term decrease in quality of life from goserelin addition (OPTION trial) 1
• This is a trade-off patients may accept if adequately informed 1
• Anti-Müllerian hormone may predict ovarian function recovery 1

Important Caveats and Pitfalls

Common Misconception: GnRH agonists are NOT a substitute for embryo/oocyte cryopreservation. 1 They preserve ovarian function (preventing early menopause), not necessarily fertility (ability to conceive).

Timing Limitation: Complete ovarian suppression requires several weeks after initiation, though this doesn't appear to affect efficacy. 4, 5

Uncertain Scenarios: No clinical data exists on whether GnRH agonists are necessary during post-neoadjuvant capecitabine, olaparib, or immunotherapy. 1

Quality of Life Trade-off: The OPTION trial demonstrated short-term QOL decrease, including menopausal symptoms like hot flashes. 1, 5 Patients must be counseled on this expected side effect.

Measurement Endpoint: Most studies use resumption of menstruation as the endpoint rather than actual fertility, which explains some controversy in the literature. 4, 6

Strength of Evidence

The evidence base includes 20 studies (15 retrospective, 5 RCTs) with 1,837 patients showing significant decrease in premature ovarian failure (91% preserved cyclic function vs 41% controls), with seven meta-analyses supporting benefit. 6 However, nine studies with 593 patients showed no benefit, explaining ongoing controversy. 6

The most recent and authoritative guideline (ESO-ESMO 2022) has resolved this controversy in favor of offering GnRH agonists to all patients for ovarian function preservation. 1